4.8 Article

A gating mechanism for Pi release governs the mRNA unwinding by eIF4AI during translation initiation

Journal

NUCLEIC ACIDS RESEARCH
Volume 43, Issue 21, Pages 10157-10167

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkv1033

Keywords

-

Funding

  1. Ministry of Science and Technology of China [2015CB910304]
  2. Hi-Tech Research and Development Program of China [2012AA020301, 2012AA01A305, 2012AA020302]
  3. National Natural Science Foundation of China [81430084, 21472208, 31270830, 21572038]
  4. State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
  5. Fudan University
  6. State Key Laboratory of Toxicology and Medical Countermeasures, Academy of Military Medical Science [TMC201505]

Ask authors/readers for more resources

Eukaryotic translation initiation factor eIF4AI, the founding member of DEAD-box helicases, undergoes ATP hydrolysis-coupled conformational changes to unwind mRNA secondary structures during translation initiation. However, the mechanism of its coupled enzymatic activities remains unclear. Here we report that a gating mechanism for Pi release controlled by the inter-domain linker of eIF4AI regulates the coupling between ATP hydrolysis and RNA unwinding. Molecular dynamic simulations and experimental results revealed that, through forming a hydrophobic core with the conserved SAT motif of the N-terminal domain and I357 from the C-terminal domain, the linker gated the release of Pi from the hydrolysis site, which avoided futile hydrolysis cycles of eIF4AI. Further mutagenesis studies suggested this linker also plays an auto-inhibitory role in the enzymatic activity of eIF4AI, which may be essential for its function during translation initiation. Overall, our results reveal a novel regulatory mechanism that controls eIF4AI-mediated mRNA unwinding and can guide further mechanistic studies on other DEAD-box helicases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Cell Biology

The nuclear bodies formed by histone demethylase KDM7A

Hui Ming, Qianfeng Wang, Yuwen Zhang, Luzhang Ji, Lu Cheng, Xiangru Huo, Zixiang Yan, Zhexiao Liu, Yongjun Dang, Bo Wen

PROTEIN & CELL (2021)

Article Chemistry, Medicinal

Agonist Lock Touched and Untouched Retinoic Acid Receptor-Related Orphan Receptor-γt (RORγt) Inverse Agonists: Classification Based on the Molecular Mechanisms of Action

Nannan Sun, Qiong Xie, Yongjun Dang, Yonghui Wang

Summary: ROR gamma t is a potential drug target for autoimmune diseases with complex relationship between agonist lock and inverse agonism. Different inverse agonists adopt different interference mechanisms.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Oncology

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness

Richard Lewis, H. Carlo Maurer, Nikita Singh, Irene Gonzalez-Menendez, Matthias Wirth, Markus Schick, Le Zhang, Konstandina Isaakidis, Anna Katharina Scherger, Veronika Schulze, Junyan Lu, Thorsten Zenz, Katja Steiger, Roland Rad, Leticia Quintanilla-Martinez, Marion Espeli, Karl Balabanian, Ulrich Keller, Stefan Habringer

Summary: The study reveals that hyperactivation of CXCR4 is identified as a co-driver of an aggressive lymphoma phenotype.

LEUKEMIA (2021)

Article Oncology

The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision

Friederike Herbst, Tonio J. L. Lang, Elias S. P. Eckert, Peer Wunsche, Alexander A. Wurm, Tim Kindinger, Karin Laaber, Shayda Hemmati, Agnes Hotz-Wagenblatt, Oksana Zavidij, Anna Paruzynski, Junyan Lu, Christof von Kalle, Thorsten Zenz, Christoph Klein, Manfred Schmidt, Claudia R. Ball, Hanno Glimm

Summary: The EVL/MIR342 gene locus is identified as a hotspot for therapeutic vector insertions in human hematopoietic stem and progenitor cells, with EVL and its intronic miRNA-342 regulating hematopoiesis by promoting lymphopoiesis and myeloid colony formation respectively. MiR-342 counteracts its host gene EVL, targeting lymphoid signaling pathways and reducing pre-B-cell output, highlighting a balance between the two factors in determining hematopoietic cell fate.

LEUKEMIA (2021)

Letter Oncology

SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

Marco M. Buhler, Junyan Lu, Sebastian Scheinost, Ferran Nadeu, Damien Roos-Weil, Manfred Hensel, Tharshika Thavayogarajah, Holger Moch, Markus G. Manz, Eugenia Haralambieva, Ewerton Marques Maggio, Silvia Bea, Eva Gine, Elias Campo, Olivier A. Bernard, Wolfgang Huber, Thorsten Zenz

LEUKEMIA RESEARCH (2021)

Article Multidisciplinary Sciences

Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide

Haikun Song, Cen Wang, Chenggang Zhu, Ziying Wang, Huiya Yang, Peng Wu, Xiaotian Cui, Juan Botas, Yongjun Dang, Yu Ding, Yiyan Fei, Boxun Lu

Summary: Chemical binders targeting mutant huntingtin protein (mHTT) have the potential to inhibit Huntington's disease (HD) by destabilizing the protein through enhancing its polyubiquitination.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Biochemistry & Molecular Biology

Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL

Peter-Martin Bruch, Holly A. R. Giles, Carolin Kolb, Sophie A. Herbst, Tina Becirovic, Tobias Roider, Junyan Lu, Sebastian Scheinost, Lena Wagner, Jennifer Huellein, Ivan Berest, Mark Kriegsmann, Katharina Kriegsmann, Christiane Zgorzelski, Peter Dreger, Judith B. Zaugg, Carsten Mueller-Tidow, Thorsten Zenz, Wolfgang Huber, Sascha Dietrich

Summary: The tumor microenvironment and genetic alterations play a collective role in influencing the efficacy of cancer drugs. This study investigated the impact of microenvironmental stimuli on drug response in chronic lymphocytic leukemia (CLL) patients and identified distinct subgroups with different clinical outcomes. The researchers also found that trisomy 12 samples exhibited amplified response to multiple microenvironmental stimuli and had a unique epigenetic signature. Additionally, interleukin 4 (IL4) and Toll-like receptor (TLR) signaling were identified as strong contributors to drug resistance. The findings highlight the importance of considering both microenvironmental factors and genetic alterations in cancer treatment.

MOLECULAR SYSTEMS BIOLOGY (2022)

Article Hematology

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression br

Pau Abrisqueta, Daniel Medina, Guillermo Villacampa, Junyan Lu, Miguel Alcoceba, Julia Carabia, Joan Boix, Barbara Tazon-Vega, Gloria Iacoboni, Sabela Bobillo, Ana Marin-Niebla, Marcos Gonzalez, Thorsten Zenz, Marta Crespo, Francesc Bosch

Summary: This study developed a gene expression-based prediction model for early progression in chronic lymphocytic leukemia (CLL). By analyzing 200 genes related to microenvironment signaling, the CLL15 assay was found to be significantly associated with time to first treatment (TtFT) in both the training and validation cohorts. The CLL15 score demonstrated improved prognostic capacity compared to other indicators, such as IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL.

BLOOD ADVANCES (2022)

Article Multidisciplinary Sciences

FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis

Allison Mitchell, Ling Wu, C. James Block, Mu Zhang, Justin Hackett, Douglas B. Craig, Wei Chen, Yongzhong Zhao, Bin Zhang, Yongjun Dang, Xiaohong Zhang, Shengping Zhang, Chuangui Wang, Heather Gibson, Lori A. Pile, Benjamin Kidder, Larry Matherly, Zhe Yang, Yali Dou, Guojun Wu

Summary: The study reveals that FOXQ1 recruits the MLL/KMT2 histone methyltransferase complex as a transcriptional coactivator to initiate EMT in breast cancer. Disruption of FOXQ1-RbBP5 interaction or pharmacologic targeting of KMT2/MLL recruitment inhibits FOXQ1-dependent gene expression, EMT, and in vivo tumor progression. Targeting the FOXQ1-MLL epigenetic axis could be a promising strategy against metastatic progression in triple-negative breast cancer.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Sophie A. Herbst, Mattias Vesterlund, Alexander J. Helmboldt, Rozbeh Jafari, Ioannis Siavelis, Matthias Stahl, Eva C. Schitter, Nora Liebers, Berit J. Brinkmann, Felix Czernilofsky, Tobias Roider, Peter-Martin Bruch, Murat Iskar, Adam Kittai, Ying Huang, Junyan Lu, Sarah Richter, Georgios Mermelekas, Husen Muhammad Umer, Mareike Knoll, Carolin Kolb, Angela Lenze, Xiaofang Cao, Cecilia Osterholm, Linus Wahnschaffe, Carmen Herling, Sebastian Scheinost, Matthias Ganzinger, Larry Mansouri, Katharina Kriegsmann, Mark Kriegsmann, Simon Anders, Marc Zapatka, Giovanni Del Poeta, Antonella Zucchetto, Riccardo Bomben, Valter Gattei, Peter Dreger, Jennifer Woyach, Marco Herling, Carsten Muller-Tidow, Richard Rosenquist, Stephan Stilgenbauer, Thorsten Zenz, Wolfgang Huber, Eugen Tausch, Janne Lehtioe, Sascha Dietrich

Summary: Cancer heterogeneity at the proteome level can explain therapy response and prognosis differences. This study focuses on chronic lymphocytic leukemia (CLL) and identifies a new subgroup of patients, ASB-CLL, with poor prognosis. Proteomics has the potential to improve cancer patient stratification beyond genetic and transcriptomic profiling.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

Maurizio Mangolini, Alba Maiques-Diaz, Stella Charalampopoulou, Elena Gerhard-Hartmann, Johannes Bloehdorn, Andrew Moore, Giorgia Giachetti, Junyan Lu, Valar Nila Roamio Franklin, Chandra Sekkar Reddy Chilamakuri, Ilias Moutsopoulos, Andreas Rosenwald, Stephan Stilgenbauer, Thorsten Zenz, Irina Mohorianu, Clive D'Santos, Silvia Deaglio, Daniel J. Hodson, Jose Martin-Subero, Ingo Ringshausen

Summary: Mutations in NOTCH1 and NOTCH2 contribute to immune escape of malignant B cells by up-regulating PD-L1 and silencing the HLA-II locus, possibly affecting the effectiveness of immune therapies.

NATURE COMMUNICATIONS (2022)

Article Biochemical Research Methods

Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling

Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber

Summary: The development of cancer therapies can be improved by discovering tumor-specific molecular dependencies. A mathematical model, called DepInfeR, was developed to computationally infer specific molecular dependencies of individual cancers using protein-drug affinity data. This method accurately identified known protein kinase dependencies and uncovered new subgroup-specific dependencies.

PLOS COMPUTATIONAL BIOLOGY (2022)

Article Cell Biology

Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression

Veronika Ecker, Lisa Brandmeier, Martina Stumpf, Piero Giansanti, Aida Varela Moreira, Lisa Pfeuffer, Marcel H. . A. M. Fens, Junyan Lu, Bernhard Kuster, Thomas Engleitner, Simon Heidegger, Roland Rad, Ingo Ringshausen, Thorsten Zenz, Clemens-Martin Wendtner, Markus Muschen, Julia Jellusova, Jurgen Ruland, Maike Buchner

Summary: Inhibition of the phosphatases DUSP1 and DUSP6 reduces cell survival and induces cell death in chronic lymphocytic leukemia. Transient inhibition of DUSP1/6 shows promise as a treatment concept for drug-resistant CLL.

CELL REPORTS (2023)

Article Oncology

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Nora Liebers, Peter-Martin Bruch, Tobias Terzer, Miguel Hernandez-Hernandez, Nagarajan Paramasivam, Donnacha Fitzgerald, Heidi Altmann, Tobias Roider, Carolin Kolb, Mareike Knoll, Angela Lenze, Uwe Platzbecker, Christoph Roellig, Claudia Baldus, Hubert Serve, Martin Bornhaeuser, Daniel Huebschmann, Carsten Mueller-Tidow, Friedrich Stoelzel, Wolfgang Huber, Axel Benner, Thorsten Zenz, Junyan Lu, Sascha Dietrich

Summary: This study conducted a prospective non-interventional trial to investigate the potential of ex vivo drug response profiling for treatment guidance in hematologic malignancies. The results showed that ex vivo drug response profiling has the potential to predict chemotherapy response and improve risk stratification.

NATURE CANCER (2023)

Article Oncology

Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia

Junyan Lu, Ester Cannizzaro, Fabienne Meier-Abt, Sebastian Scheinost, Peter-Martin Bruch, Holly A. R. Giles, Almut Lutge, Jennifer Huellein, Lena Wagner, Brian Giacopelli, Ferran Nadeu, Julio Delgado, Elias Campo, Maurizio Mangolini, Ingo Ringshausen, Martin Bottcher, Dimitrios Mougiakakos, Andrea Jacobs, Bernd Bodenmiller, Sascha Dietrich, Christopher C. Oakes, Thorsten Zenz, Wolfgang Huber

Summary: Huber and colleagues identified a proliferative drive axis involving mTOR, MYC, and OXPHOS metabolic activity in CLL, which is associated with disease heterogeneity and outcome. Their multi-omic analysis revealed a biological axis of heterogeneity strongly linked to clinical behavior and orthogonal to known biomarkers. The CLL proliferative drive axis was validated in multiple cohorts and is a key determinant of disease outcome.

NATURE CANCER (2021)

No Data Available